Cargando…
Effects of Unsuppressed Endogenous Insulin on Pharmacokinetics and/or Pharmacodynamics of Study Insulin in the Healthy: A Retrospective Study
C‐peptide, a marker of endogenous insulin, should be consistently inhibited during euglycemic clamping, while an elevated postdosing C‐peptide (CP(postdosing)) is not an occasional phenomenon. This was a retrospective study that included 33 men who underwent a manual euglycemic clamp with a subcutan...
Autores principales: | Liu, Hui, Yu, Hongling, Sun, Lisi, Qiao, Jingtao, Li, Jiaqi, Tan, Huiwen, Yu, Yerong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546084/ https://www.ncbi.nlm.nih.gov/pubmed/35384402 http://dx.doi.org/10.1002/cpdd.1093 |
Ejemplares similares
-
Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males
por: Liu, Hui, et al.
Publicado: (2021) -
Author Correction: Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males
por: Liu, Hui, et al.
Publicado: (2021) -
How to Achieve Sufficient Endogenous Insulin Suppression in Euglycemic Clamps Assessing the Pharmacokinetics and Pharmacodynamics of Long-Acting Insulin Preparations Employing Healthy Volunteers
por: Liu, Hui, et al.
Publicado: (2022) -
Commentary: Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study
por: Liu, Hui, et al.
Publicado: (2022) -
Pharmacokinetics, pharmacodynamics, and safety of prandial oral insulin (N11005) in healthy subjects
por: Pan, Qi, et al.
Publicado: (2023)